Physiochemical drug properties associated with in vivo toxicological outcomes

被引：697

作者：

Hughes, Jason D. ^{[1
]}

Blagg, Julian ^{[2
]}

Price, David A. ^{[3
]}

Bailey, Simon ^{[4
]}

DeCrescenzo, Gary A. ^{[5
]}

Devraj, Rajesh V. ^{[5
]}

Ellsworth, Edmund ^{[6
]}

Fobian, Yvette M. ^{[5
]}

Gibbs, Michael E. ^{[3
]}

Gilles, Richard W. ^{[5
]}

Greene, Nigel ^{[3
]}

Huang, Enoch ^{[1
]}

Krieger-Burke, Teresa ^{[6
]}

Loesel, Jens ^{[7
]}

Wager, Travis ^{[3
]}

Whiteley, Larry ^{[5
]}

Zhang, Yao ^{[3
]}

机构：

[1] Pfizer Res Technol Ctr, Cambridge, MA 02139 USA

[2] Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

[3] Pfizer Inc, Groton, CT 06340 USA

[4] Pfizer, San Diego, CA 92121 USA

[5] Pfizer, St Louis, MO 63017 USA

[6] Pfizer, Ann Arbor, MI 48105 USA

[7] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 17期

关键词：

toxicity; polar surface area; ClogP; adverse events;

D O I：

10.1016/j.bmcl.2008.07.071

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Relationships between physicochemical drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclinical Pfizer compounds; an increased likelihood of toxic events was found for less polar, more lipophilic compounds. This trend held across a wide range of types of toxicity and across a broad swath of chemical space. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4872 / 4875

页数：4

共 50 条

[11] IMPACT OF PILL-SPLITTING TRAINING ON DRUG PHYSIOCHEMICAL PROPERTIES, COMPLIANCE AND CLINICAL OUTCOMES IN ELDERLY POPULATION: A CROSS-OVER COHORT STUDY
Lee, V. W. Y.
Yu, Y.
Tang, L.
Yan, B.
VALUE IN HEALTH, 2013, 16 (07) : A514 - A514
[12] Effects of Charge, Size and Physiochemical Properties of Polypeptides on their Transport into Cartilage: Implications for Drug Delivery
Bajpayee, A. G.
Chen, W.
Ribbeck, K.
Grodzinsky, A. J.
TISSUE ENGINEERING PART A, 2015, 21 : S404 - S404
[13] In vivo Toxicological Evaluation of Polyhydroxyalkanoates
E. I. Shishatskaya
T. G. Volova
I. I. Gitelson
Doklady Biological Sciences, 2002, 383 (1-6) : 109 - 111
[14] In vivo toxicological evaluation of Anisomycin
Tang Zhengle
Xing Feiyue
Chen Di
Yu Yu
Yu Chunyan
Di Jingfang
Liu Jing
TOXICOLOGY LETTERS, 2012, 208 (01) : 1 - 11
[15] A Study of the Comparability of the Pharmacodynamic, Toxicological, and Pharmacokinetic Properties of the Reference Drug Pulmozyme® and the Biosimilar Drug Tigerase®
Aksenova, M. S.
Bocharova, E. N.
Abbasova, S. G.
Ponomarev, A. S.
Loginova, V. V.
Bolotnikova, M. V.
Belskaya, N. V.
Kazarov, A. A.
Lisova, A. E.
Kudina, N. K.
Pantyushenko, M. S.
Zhilyaeva, M. V.
Kopein, D. S.
Karelov, Yu. M.
Erastov, G. G.
Lykov, M. V.
Khamitov, R. A.
DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2024, 519 (01) : 525 - 533
[16] Analysis of ToxCast data - In vitro and physiochemical properties - In the accurate classification of chemicals that induce hepatocarcinogenesis in vivo
Borotkanics, R.
Locke, P.
Trush, M.
TOXICOLOGY LETTERS, 2016, 258 : S76 - S76
[17] Sterodin®, a novel immunostimulating drug: Some toxicological and pharmacological evaluations in vivo, and drug-lipid interaction studies in vitro
Ray, Sarbani Dey
Roy, Partha Pratim
Ray, Supratim
ACTA PHARMACEUTICA, 2009, 59 (03) : 325 - 334
[18] Toxicological Consequences of Drug-Drug Interactions
Walsh, Rachel J.
Srivastava, Abhishek
Antoine, Daniel J.
Williams, Dominic P.
Park, B. Kevin
ENZYME- AND TRANSPORTER-BASED DRUG-DRUG INTERACTIONS: PROGRESS AND FUTURE CHALLENGES, 2010, : 651 - 664
[19] TOXICOLOGICAL IMPLICATIONS OF DRUG BIOTRANSFORMATION
BIRKETT, DJ
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1981, 8 (04) : 423 - 423
[20] TURKEY TENDERNESS AND ASSOCIATED PHYSIOCHEMICAL PARAMETERS
MARION, WW
FEEDSTUFFS, 1971, 43 (14): : 24 - &

← 1 2 3 4 5 →